Binding Site Information of Target
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T80975 | Target Info | |||
| Target Name | Vascular endothelial growth factor receptor 2 (KDR) | ||||
| Synonyms | VEGFR2; VEGFR-2; VEGF-2 receptor; Protein-tyrosine kinase receptor flk-1; Kinase insert domain receptor; Fetal liver kinase 1; FLK1; FLK-1; CD309 | ||||
| Target Type | Successful Target | ||||
| Gene Name | KDR | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Tivozanib | Ligand Info | |||||
| Structure Description | CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951) | PDB:4ASE | ||||
| Method | X-ray diffraction | Resolution | 1.83 Å | Mutation | Yes | [1] |
| PDB Sequence |
DPDELPLDEH
816 CERLPYDASK826 WEFPRDRLKL836 GKPLGRGAFG846 QVIEADAFGI856 DKTATCRTVA 866 VKMLKEGATH876 SEHRALMSEL886 KILIHIGHHL896 NVVNLLGACT906 KPGGPLMVIV 916 EFCKFGNLST926 YLRSKRNEFV936 PYKYKDFLTL1002 EHLICYSFQV1012 AKGMEFLASR 1022 KCIHRDLAAR1032 NILLSEKNVV1042 KICDFGLARD1052 IYKDPDYVRK1062 GDARLPLKWM 1072 APETIFDRVY1082 TIQSDVWSFG1092 VLLWEIFSLG1102 ASPYPGVKID1112 EEFCRRLKEG 1122 TRMRAPDYTT1132 PEMYQTMLDC1142 WHGEPSQRPT1152 FSELVEHLGN1162 LLQANAQ |
|||||
|
|
LEU840
3.427
GLY841
3.790
VAL848
3.519
ALA866
3.470
LYS868
3.465
GLU885
2.985
ILE888
4.514
LEU889
3.626
ILE892
4.295
VAL898
4.676
VAL899
3.313
VAL914
3.991
VAL916
3.519
|
|||||
| Ligand Name: Sunitinib | Ligand Info | |||||
| Structure Description | CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2-diethylaminoethyl)-5-((Z)-(5- fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3- carboxamide) | PDB:4AGD | ||||
| Method | X-ray diffraction | Resolution | 2.81 Å | Mutation | Yes | [1] |
| PDB Sequence |
LSIVMDPDEL
811 PLPYDASKWE828 FPRDRLKLGK838 PLGRGAFGQV848 IEADAFGIDK858 TATCRTVAVK 868 MLKEGATHSE878 HRALMSELKI888 LIHIGHHLNV898 VNLLGACTKP908 GGPLMVIVEF 918 CKFGNLSTYL928 RSKRNEFVPY938 YKDFLTLEHL1005 ICYSFQVAKG1015 MEFLASRKCI 1025 HRDLAARNIL1035 LSEKNVVKIC1045 DFGLARDIYK1055 DPDYVRKGDA1065 RLPLKWMAPE 1075 TIFDRVYTIQ1085 SDVWSFGVLL1095 WEIFSLGASP1105 YPGVKIDEEF1115 CRRLKEGTRM 1125 RAPDYTTPEM1135 YQTMLDCWHG1145 EPSQRPTFSE1155 LVEHLGNLLQ1165 ANAQ |
|||||
|
|
||||||
| Ligand Name: Axitinib | Ligand Info | |||||
| Structure Description | CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-Methyl-2-(3-((E)-2-pyridin-2-yl-vinyl)-1H- indazol-6-ylsulfanyl)-benzamide) | PDB:4AG8 | ||||
| Method | X-ray diffraction | Resolution | 1.95 Å | Mutation | Yes | [1] |
| PDB Sequence |
HCERLPYDAS
825 KWEFPRDRLK835 LGKPLGRGAF845 GQVIEADAFG855 IDKTATCRTV865 AVKMLKEGAT 875 HSEHRALMSE885 LKILIHIGHH895 LNVVNLLGAC905 TKPGGPLMVI915 VEFCKFGNLS 925 TYLRSKRNEF935 VPYYKDFLTL1002 EHLICYSFQV1012 AKGMEFLASR1022 KCIHRDLAAR 1032 NILLSEKNVV1042 KICDFGLARD1052 IYKDPDYVRK1062 GDARLPLKWM1072 APETIFDRVY 1082 TIQSDVWSFG1092 VLLWEIFSLG1102 ASPYPGVKID1112 EEFCRRLKEG1122 TRMRAPDYTT 1132 PEMYQTMLDC1142 WHGEPSQRPT1152 FSELVEHLGN1162 LLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .AXI or .AXI2 or .AXI3 or :3AXI;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:889 or .A:899 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1035 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.820
VAL848
3.633
ALA866
3.329
VAL867
4.109
LYS868
3.502
GLU885
2.697
LEU889
4.043
VAL899
3.463
VAL914
3.330
ILE915
4.790
VAL916
3.489
|
|||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: Intedanib | Ligand Info | |||||
| Structure Description | Structure of VEGFR2 kinase domain in complex with BIBF1120 | PDB:3C7Q | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | No | [2] |
| PDB Sequence |
RLPYDASKWE
828 FPRDRLKLGK838 PLGRGAFGQV848 IEADAFGIDK858 TATRTVAVKM869 LKEGATHSEH 879 RALMSELKIL889 IHIGHHLNVV899 NLLGACTKPG909 GPLMVIVEFC919 KFGNLSTYLR 929 SKRNEFVPYK939 DFLTLEHLIY1008 SFQVAKGMEF1018 LASRKIHRDL1029 AARNILLSEK 1039 NVVKICDFDI1053 KDPDVRKGDA1065 RLPLKWMAPE1075 TIFDRVYTIQ1085 SDVWSFGVLL 1095 WEIFSLGASP1105 YPGVKIDEEF1115 CRRLKEGTRM1125 RAPDYTTPEM1135 YQTMLDCWHG 1145 EPSQRPTFSE1155 LVEHLGNLLQ1165 ANAQQD
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .XIN or .XIN2 or .XIN3 or :3XIN;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:850 or .A:866 or .A:868 or .A:885 or .A:889 or .A:899 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:923 or .A:1035 or .A:1045 or .A:1046; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.670
GLY841
3.872
VAL848
4.043
GLU850
3.203
ALA866
3.644
LYS868
2.759
GLU885
4.130
LEU889
4.418
VAL899
3.485
VAL916
3.358
|
|||||
| Ligand Name: Lenvatinib | Ligand Info | |||||
| Structure Description | KDR in complex with ligand lenvatinib | PDB:3WZD | ||||
| Method | X-ray diffraction | Resolution | 1.57 Å | Mutation | Yes | [3] |
| PDB Sequence |
LPYDASKWEF
829 PRDRLKLGKP839 LGGQVIEADA853 FGIDKTATCR863 TVAVKMLKEG873 ATHSEHRALM 883 SELKILIHIG893 HHLNVVNLLG903 ACTKPGGPLM913 VIVEFCKFGN923 LSTYLRSKRN 933 EFVPYKVAPE993 DLYKDFLTLE1003 HLICYSFQVA1013 KGMEFLASRK1023 CIHRDLAARN 1033 ILLSEKNVVK1043 ICDFGLALPL1069 KWMAPETIFD1079 RVYTIQSDVW1089 SFGVLLWEIF 1099 SLGASPYPGV1109 KIDEEFCRRL1119 KEGTRMRAPD1129 YTTPEMYQTM1139 LDCWHGEPSQ 1149 RPTFSELVEH1159 LGNLLQAN
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .LEV or .LEV2 or .LEV3 or :3LEV;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:868 or .A:885 or .A:888 or .A:889 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1035 or .A:1045 or .A:1046 or .A:1047 or .A:1049; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.807
GLY841
3.150
VAL848
3.964
ALA866
3.536
LYS868
3.745
GLU885
2.861
ILE888
3.566
LEU889
3.771
VAL899
3.595
VAL914
4.588
VAL916
3.790
|
|||||
| Ligand Name: Sorafenib | Ligand Info | |||||
| Structure Description | KDR in complex with ligand sorafenib | PDB:3WZE | ||||
| Method | X-ray diffraction | Resolution | 1.90 Å | Mutation | Yes | [3] |
| PDB Sequence |
EHCERLPYDA
824 SKWEFPRDRL834 KLGKPLGRGA844 FGQVIEADAF854 GIDKTATCRT864 VAVKMLKEGA 874 THSEHRALMS884 ELKILIHIGH894 HLNVVNLLGA904 CTKPGGPLMV914 IVEFCKFGNL 924 STYLRSKRNE934 FVPYKDLYKD998 FLTLEHLICY1008 SFQVAKGMEF1018 LASRKCIHRD 1028 LAARNILLSE1038 KNVVKICDFG1048 LARDIYKDPD1058 YVRKGARLPL1069 KWMAPETIFD 1079 RVYTIQSDVW1089 SFGVLLWEIF1099 SLGASPYPGV1109 KIDEEFCRRL1119 KEGTRMRAPD 1129 YTTPEMYQTM1139 LDCWHGEPSQ1149 RPTFSELVEH1159 LGNLLQAN
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .BAX or .BAX2 or .BAX3 or :3BAX;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1025 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.643
VAL848
3.320
ALA866
3.467
LYS868
3.736
GLU885
2.698
ILE888
4.204
LEU889
3.744
ILE892
3.651
VAL898
3.658
VAL899
3.378
VAL916
3.533
GLU917
3.279
PHE918
3.509
|
|||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: PF-00337210 | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with PF- 00337210 (N,2-dimethyl-6-(7-(2-morpholinoethoxy)quinolin-4-yloxy) benzofuran-3-carboxamide) | PDB:2XIR | ||||
| Method | X-ray diffraction | Resolution | 1.50 Å | Mutation | Yes | [4] |
| PDB Sequence |
HCERLPYDAS
825 KWEFPRDRLK835 LGKPLGRGAF845 GQVIEADAFG855 IDKTATCRTV865 AVKMLKEGAT 875 HSEHRALMSE885 LKILIHIGHH895 LNVVNLLGAC905 TKPGGPLMVI915 VEFCKFGNLS 925 TYLRSKRNEF935 VPYYKDFLTL1002 EHLICYSFQV1012 AKGMEFLASR1022 KCIHRDLAAR 1032 NILLSEKNVV1042 KICDFGLARD1052 IYKDPDYVRK1062 GDARLPLKWM1072 APETIFDRVY 1082 TIQSDVWSFG1092 VLLWEIFSLG1102 ASPYPGVKID1112 EEFCRRLKEG1122 TRMRAPDYTT 1132 PEMYQTMLDC1142 WHGEPSQRPT1152 FSELVEHLGN1162 LLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .00J or .00J2 or .00J3 or :300J;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:868 or .A:885 or .A:889 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1035 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: Phosphonotyrosine | Ligand Info | |||||
| Structure Description | Vegfr2 in complex with a novel 4-amino-furo[2,3-d]pyrimidine | PDB:1YWN | ||||
| Method | X-ray diffraction | Resolution | 1.71 Å | Mutation | Yes | [5] |
| PDB Sequence |
LPYDASKWEF
827 PRDRLKLGKP837 LGRGAFGQVI847 EADAFGIDKT857 ATCRTVAVKM867 LTHSEHRALM 881 SELKILIHIG891 HHLNVVNLLG901 ACTKPGGPLM911 VIVEFCKFGN921 LSTYLRSKRN 931 EFVPFLTLEH1002 LICYSFQVAK1012 GMEFLASRKC1022 IHRDLAARNI1032 LLSEKNVVKI 1042 CDIKDPDVRK1060 GDARLPLKWM1070 APETIFDRVY1080 TIQSDVWSFG1090 VLLWEIFSLG 1100 ASPYPGVKID1110 EEFCRRLKEG1120 TRMRAPDYTT1130 PEMYQTMLDC1140 WHGEPSQRPT 1150 FSELVEHLGN1160 LLQANAQQD
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PTR or .PTR2 or .PTR3 or :3PTR;style chemicals stick;color identity;select .A:840 or .A:841 or .A:842 or .A:1051 or .A:1053 or .A:1054 or .A:1055 or .A:1056 or .A:1058 or .A:1059 or .A:1062; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: S,S-(2-Hydroxyethyl)Thiocysteine | Ligand Info | |||||
| Structure Description | Structure of VEGFR2 kinase domain in complex with BIBF1120 | PDB:3C7Q | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | No | [2] |
| PDB Sequence |
RLPYDASKWE
828 FPRDRLKLGK838 PLGRGAFGQV848 IEADAFGIDK858 TATRTVAVKM869 LKEGATHSEH 879 RALMSELKIL889 IHIGHHLNVV899 NLLGACTKPG909 GPLMVIVEFC919 KFGNLSTYLR 929 SKRNEFVPYK939 DFLTLEHLIY1008 SFQVAKGMEF1018 LASRKIHRDL1029 AARNILLSEK 1039 NVVKICDFDI1053 KDPDVRKGDA1065 RLPLKWMAPE1075 TIFDRVYTIQ1085 SDVWSFGVLL 1095 WEIFSLGASP1105 YPGVKIDEEF1115 CRRLKEGTRM1125 RAPDYTTPEM1135 YQTMLDCWHG 1145 EPSQRPTFSE1155 LVEHLGNLLQ1165 ANAQQD
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .CME or .CME2 or .CME3 or :3CME;style chemicals stick;color identity;select .A:833 or .A:835 or .A:852 or .A:853 or .A:854 or .A:855 or .A:860 or .A:861 or .A:863 or .A:864 or .A:888 or .A:891 or .A:892 or .A:1002 or .A:1003 or .A:1004 or .A:1005 or .A:1006 or .A:1008 or .A:1009 or .A:1010 or .A:1011 or .A:1012 or .A:1019 or .A:1020 or .A:1022 or .A:1023 or .A:1025 or .A:1026 or .A:1040 or .A:1084 or .A:1087 or .A:1164; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ARG833
4.277
LYS835
4.219
ASP852
3.111
ALA853
3.452
PHE854
3.334
GLY855
4.798
ALA860
4.459
THR861
1.334
ARG863
1.328
THR864
4.334
ILE888
4.301
HIS891
3.637
ILE892
3.100
LEU1002
4.696
GLU1003
3.000
HIS1004
3.179
LEU1005
3.292
|
|||||
| Ligand Name: AAL-993 | Ligand Info | |||||
| Structure Description | Human Vascular Endothelial Growth Factor Receptor 2 (KDR) Kinase Domain in complex with AAL993 | PDB:5EW3 | ||||
| Method | X-ray diffraction | Resolution | 2.50 Å | Mutation | No | [6] |
| PDB Sequence |
PYDASKWEFP
830 RDRLKLGKPL840 GRGAFGQVIE850 ADAFGIDKTA860 TCRTVAVKML870 KEGATHSEHR 880 ALMSELKILI890 HIGHHLNVVN900 LLGACTKPGG910 PLMVIVEFCK920 FGNLSTYLRS 930 KRNEFVPYKV940 KDFLTLEHLI1006 CYSFQVAKGM1016 EFLASRKCIH1026 RDLAARNILL 1036 SEKNVVKICD1046 FGLPLKWMAP1074 ETIFDRVYTI1084 QSDVWSFGVL1094 LWEIFSLGAS 1104 PYPGVKIDEE1114 FCRRLKEGTR1124 MRAPDYTTPE1134 MYQTMLDCWH1144 GEPSQRPTFS 1154 ELVEHLGNLL1164 QANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .5T2 or .5T22 or .5T23 or :35T2;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
4.038
VAL848
3.644
ALA866
3.574
VAL867
3.920
LYS868
3.553
GLU885
2.890
ILE888
4.934
LEU889
3.797
ILE892
3.805
VAL898
3.344
VAL899
3.577
VAL914
3.460
|
|||||
| Ligand Name: Motesanib | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with motesanib | PDB:3EFL | ||||
| Method | X-ray diffraction | Resolution | 2.20 Å | Mutation | Yes | [7] |
| PDB Sequence |
AERLPYDASK
826 WEFPRDRLKL836 GKPLGRGGQV848 IEADAFGIDT861 CRTVAVKMLK871 ETHSEHRALM 883 SELKILIHIG893 HHLNVVNLLG903 ACTKPGGPLM913 VIVEFCKFGN923 LSTYLRSKRN 933 EFVPYKVAPE993 DLYKDFLTLE1003 HLICYSFQVA1013 KGMEFLASRK1023 CIHRDLAARN 1033 ILLSEKNVVK1043 ICDFGPLKWM1072 APETIFDRVY1082 TIQSDVWSFG1092 VLLWEIFSLG 1102 ASPYPGVKID1112 EEFCRRLKEG1122 TRMRAPDYTT1132 PEMYQTMLDC1142 WHGEPSQRPT 1152 FSELVEHLGN1162 LLQANAQQDR1172 HHHHHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .706 or .7062 or .7063 or :3706;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:1019 or .A:1024 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.858
VAL848
3.499
ALA866
3.617
VAL867
3.771
LYS868
3.404
GLU885
3.100
ILE888
4.459
LEU889
3.746
ILE892
3.512
VAL898
4.632
VAL899
3.337
VAL914
3.538
|
|||||
| Ligand Name: Cysteine Sulfenic Acid | Ligand Info | |||||
| Structure Description | Crystal structure of VEGFR2 in complex with a 3,4,5-trimethoxy aniline containing pyrimidine | PDB:3CJF | ||||
| Method | X-ray diffraction | Resolution | 2.15 Å | Mutation | No | [8] |
| PDB Sequence |
CERLPYDASK
824 WEFPRDRLNL834 GKPLGRGAFG844 QVIEADAFGI854 DKTATRTVAV865 KMLKEGATHS 875 EHRALMSELK885 ILIHIGHHLN895 VVNLLGACTK905 PGGPLMVIVE915 FCKFGNLSTY 925 LRSKRNEFVP935 YKKDFLTLEH1002 LIYSFQVAKG1013 MEFLASRKIH1024 RDLAARNILL 1034 SEKNVVKIDL1047 ARDIYKPLKW1069 MAPETIFDRV1079 YTIQSDVWSF1089 GVLLWEIFSL 1099 GASPYPGVKI1109 DEEFRRLKEG1120 TRMRAPDYTT1130 PEMYQTMLDC1140 WHGEPSQRPT 1150 FSELVEHLGN1160 LLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .CSO or .CSO2 or .CSO3 or :3CSO;style chemicals stick;color identity;select .A:850 or .A:851 or .A:852 or .A:858 or .A:859 or .A:861 or .A:862 or .A:886 or .A:890 or .A:897 or .A:1000 or .A:1001 or .A:1002 or .A:1003 or .A:1004 or .A:1006 or .A:1007 or .A:1008 or .A:1009 or .A:1017 or .A:1018 or .A:1020 or .A:1021 or .A:1023 or .A:1024 or .A:1030 or .A:1031 or .A:1032 or .A:1033 or .A:1038 or .A:1041 or .A:1042 or .A:1044 or .A:1047 or .A:1048 or .A:1049 or .A:1050 or .A:1067 or .A:1075 or .A:1076 or .A:1082 or .A:1085 or .A:1110 or .A:1111 or .A:1112 or .A:1113 or .A:1115 or .A:1116 or .A:1117 or .A:1118 or .A:1162; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ASP850
4.786
ALA851
3.314
PHE852
3.457
ALA858
4.548
THR859
1.333
ARG861
1.333
THR862
4.313
ILE886
4.525
ILE890
3.712
VAL897
3.735
LEU1000
4.604
GLU1001
2.787
HIS1002
3.168
LEU1003
3.206
ILE1004
1.336
TYR1006
1.330
SER1007
3.277
PHE1008
3.393
GLN1009
2.958
LEU1017
3.043
ALA1018
4.165
ARG1020
3.362
LYS1021
1.332
ILE1023
1.325
HIS1024
2.895
ARG1030
4.823
ASN1031
2.753
ILE1032
4.653
LEU1033
4.029
ASN1038
4.795
LYS1041
3.264
ILE1042
1.332
ASP1044
1.331
LEU1047
4.687
ALA1048
4.840
ARG1049
3.407
ASP1050
4.868
LEU1067
4.830
ILE1075
3.970
PHE1076
3.852
ILE1082
3.600
ASP1085
4.785
ASP1110
3.106
GLU1111
3.618
GLU1112
3.181
PHE1113
1.333
ARG1115
1.336
ARG1116
3.331
LEU1117
3.428
LYS1118
3.073
LEU1162
3.618
|
|||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: {3-[(5-Methyl-2-Phenyl-1,3-Oxazol-4-Yl)methoxy]phenyl}methanol | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a back pocket binder | PDB:3VHK | ||||
| Method | X-ray diffraction | Resolution | 2.49 Å | Mutation | No | [9] |
| PDB Sequence |
DEHCERLPYD
823 ASKWEFPRDR833 LKLGKPLGRG843 AFGQVIEADA853 FGIDKTATCR863 TVAVKMLKEG 873 ATHSEHRALM883 SELKILIHIG893 HHLNVVNLLG903 ACTKPGGPLM913 VIVEFCKFGN 923 LSTYLRSKRN933 EFVPYKYKDF999 LTLEHLICYS1009 FQVAKGMEFL1019 ASRKCIHRDL 1029 AARNILLSEK1039 NVVKICDFGL1049 ARDIYKDPDY1059 VRKARLPLKW1071 MAPETIFDRV 1081 YTIQSDVWSF1091 GVLLWEIFSL1101 GASPYPGVKI1111 DEEFCRRLKE1121 GTRMRAPDYT 1131 TPEMYQTMLD1141 CWHGEPSQRP1151 TFSELVEHLG1161 NLLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .BPK or .BPK2 or .BPK3 or :3BPK;style chemicals stick;color identity;select .A:848 or .A:866 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:1019 or .A:1025 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: N-(Cyclopropylmethyl)-4-(methyloxy)-3-({5-[3-(3-pyridinyl)phenyl]-1,3-oxazol-2-YL}amino)benzenesulfonamide | Ligand Info | |||||
| Structure Description | Crystal structure of VEGFR2 in complex with a 2-anilino-5-aryl-oxazole inhibitor | PDB:1Y6B | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | No | [10] |
| PDB Sequence |
RLPYDASKWE
826 FPRDRLKLGK836 PLGRGGQVIE848 ADAFGIDKTA858 TCRTVAVKML868 KATHSEHRAL 880 MSELKILIHI890 GHHLNVVNLL900 GACTKPGGPL910 MVIVEFCKFG920 NLSTYLRSKR 930 NEFVPYFLTL1000 EHLICYSFQV1010 AKGMEFLASR1020 KCIHRDLAAR1030 NILLSEKNVV 1040 KICDFPLKWM1070 APETIFDRVY1080 TIQSDVWSFG1090 VLLWEIFSLG1100 ASPYPGVKID 1110 EEFCRRLKEG1120 TRMRAPDYTT1130 PEMYQTMLDC1140 WHGEPSQRPT1150 FSELVEHLGN 1160 LLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .AAX or .AAX2 or .AAX3 or :3AAX;style chemicals stick;color identity;select .A:838 or .A:839 or .A:840 or .A:841 or .A:846 or .A:848 or .A:864 or .A:865 or .A:866 or .A:883 or .A:897 or .A:912 or .A:913 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:1030 or .A:1033 or .A:1045; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU838
3.605
GLY839
3.762
ARG840
3.806
GLY841
4.142
VAL846
3.710
GLU848
4.115
ALA864
3.431
VAL865
3.979
LYS866
3.278
GLU883
2.543
VAL897
4.967
VAL912
3.331
|
|||||
| Ligand Name: N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]-1,3-oxazol-2-amine | Ligand Info | |||||
| Structure Description | Crystal structure of VEGFR2 in complex with a 2-anilino-5-aryl-oxazole inhibitor | PDB:1Y6A | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | No | [10] |
| PDB Sequence |
LPYDASKWEF
827 PRDRLKLGKP837 LGRQVIEADA851 FGIDKTATCR861 TVAVKMLTHS875 EHRALMSELK 885 ILIHIGHHLN895 VVNLLGACTK905 PGGPLMVIVE915 FCKFGNLSTY925 LRSKRNEFVP 935 YDFLTLEHLI1004 CYSFQVAKGM1014 EFLASRKCIH1024 RDLAARNILL1034 SEKNVVKICD 1044 FPLKWMAPET1074 IFDRVYTIQS1084 DVWSFGVLLW1094 EIFSLGASPY1104 PGVKIDEEFC 1114 RRLKEGTRMR1124 APDYTTPEMY1134 QTMLDCWHGE1144 PSQRPTFSEL1154 VEHLGNLLQA 1164 N
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .AAZ or .AAZ2 or .AAZ3 or :3AAZ;style chemicals stick;color identity;select .A:838 or .A:839 or .A:840 or .A:846 or .A:848 or .A:864 or .A:866 or .A:897 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:920 or .A:921 or .A:1030 or .A:1033 or .A:1045; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: 1-{2-Fluoro-4-[(5-Methyl-5h-Pyrrolo[3,2-D]pyrimidin-4-Yl)oxy]phenyl}-3-[3-(Trifluoromethyl)phenyl]urea | Ligand Info | |||||
| Structure Description | Crystal structure of human VEGFR2 kinase domain with a novel pyrrolopyrimidine inhibitor. | PDB:3VHE | ||||
| Method | X-ray diffraction | Resolution | 1.55 Å | Mutation | No | [11] |
| PDB Sequence |
LPLDEHCERL
820 PYDASKWEFP830 RDRLKLGKPL840 GRGAFGQVIE850 ADAFGIDKTA860 TCRTVAVKML 870 KEGATHSEHR880 ALMSELKILI890 HIGHHLNVVN900 LLGACTKPGG910 PLMVIVEFCK 920 FGNLSTYLRS930 KRNEFVPYKD994 LYKDFLTLEH1004 LICYSFQVAK1014 GMEFLASRKC 1024 IHRDLAARNI1034 LLSEKNVVKI1044 CDFGLARDIY1054 KDPDYVRKAR1066 LPLKWMAPET 1076 IFDRVYTIQS1086 DVWSFGVLLW1096 EIFSLGASPY1106 PGVKIDEEFC1116 RRLKEGTRMR 1126 APDYTTPEMY1136 QTMLDCWHGE1146 PSQRPTFSEL1156 VEHLGNLLQA1166 NAQ |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .42Q or .42Q2 or .42Q3 or :342Q;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.778
GLY841
4.629
VAL848
3.383
ALA866
3.420
LYS868
3.523
GLU885
2.647
ILE888
3.864
LEU889
3.808
ILE892
4.122
VAL898
3.445
VAL899
3.519
VAL914
4.442
|
|||||
| Ligand Name: 4,5,6,11-Tetrahydro-1h-Pyrazolo[4',3':6,7]cyclohepta[1,2-B]indole | Ligand Info | |||||
| Structure Description | Crystal structure of human VEGFR2 kinase domain with Compound A. | PDB:3VID | ||||
| Method | X-ray diffraction | Resolution | 2.30 Å | Mutation | No | [9] |
| PDB Sequence |
LDEHCERLPY
822 DASKWEFPRD832 RLKLGKPLGR842 GAFGQVIEAD852 AFGIDKTATC862 RTVAVKMLKE 872 GATHSEHRAL882 MSELKILIHI892 GHHLNVVNLL902 GACTKPGGPL912 MVIVEFCKFG 922 NLSTYLRSKR932 NEFVPYKEAP992 EDLYKDFLTL1002 EHLICYSFQV1012 AKGMEFLASR 1022 KCIHRDLAAR1032 NILLSEKNVV1042 KICDYKDPDY1059 VRKGDARLPL1069 KWMAPETIFD 1079 RVYTIQSDVW1089 SFGVLLWEIF1099 SLGASPYPGV1109 KIDEEFCRRL1119 KEGTRMRAPD 1129 YTTPEMYQTM1139 LDCWHGEPSQ1149 RPTFSELVEH1159 LGNLLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .4TT or .4TT2 or .4TT3 or :34TT;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:899 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1035; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: N-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(4-propan-2-yltriazol-1-yl)acetamide | Ligand Info | |||||
| Structure Description | Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 35) | PDB:6GQQ | ||||
| Method | X-ray diffraction | Resolution | 1.52 Å | Mutation | No | [12] |
| PDB Sequence |
LDEHCERLPY
822 DASKWEFPRD832 RLKLGKPLGR842 GAFGQVIEAD852 AFGIDKTATC862 RTVAVKMLKE 872 GATHSEHRAL882 MSELKILIHI892 GHHLNVVNLL902 GACTKPGGPL912 MVIVEFCKFG 922 NLSTYLRSKR932 NEFVPYKVAP942 EDLYKDFLTL1002 EHLICYSFQV1012 AKGMEFLASR 1022 KCIHRDLAAR1032 NILLSEKNVV1042 KICDFGLARD1052 IYKDPDYVRK1062 GDARLPLKWM 1072 APETIFDRVY1082 TIQSDVWSFG1092 VLLWEIFSLG1102 ASPYPGVKID1112 EEFCRRLKEG 1122 TRMRAPDYTT1132 PEMYQTMLDC1142 WHGEPSQRPT1152 FSELVEHLGN1162 LLQAN |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .F8B or .F8B2 or .F8B3 or :3F8B;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:868 or .A:885 or .A:889 or .A:892 or .A:898 or .A:899 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.422
GLY841
4.300
VAL848
3.464
ALA866
3.462
LYS868
3.637
GLU885
3.197
LEU889
3.502
ILE892
3.883
VAL898
4.224
VAL899
3.894
VAL916
3.601
GLU917
3.314
|
|||||
| Ligand Name: N-[3-[(dimethylamino)methyl]-5-methylphenyl]-2-[3-methoxy-5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]acetamide | Ligand Info | |||||
| Structure Description | Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor | PDB:6XVJ | ||||
| Method | X-ray diffraction | Resolution | 1.78 Å | Mutation | Yes | [13] |
| PDB Sequence |
LDEHCERLPY
822 DASKWEFPRD832 RLKLGKPLGR842 GAFGQVIEAD852 AFGIDKTATC862 RTVAVKMLKE 872 GATHSEHRAL882 MSELKILIHI892 GHHLNVVNLL902 GACTKPGGPL912 MVIVEFCKFG 922 NLSTYLRSKR932 NEFVPYKVAP992 EDLYKDFLTL1002 EHLICYSFQV1012 AKGMEFLASR 1022 KCIHRDLAAR1032 NILLSEKNVV1042 KICDFGLARD1052 IYKDPDYVRK1062 GDARLPLKWM 1072 APETIFDRVY1082 TIQSDVWSFG1092 VLLWEIFSLG1102 ASPYPGVKID1112 EEFCRRLKEG 1122 TRMRAPDYTT1132 PEMYQTMLDC1142 WHGEPSQRPT1152 FSELVEHLGN1162 LLQAN |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .O35 or .O352 or .O353 or :3O35;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1025 or .A:1026 or .A:1027 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.568
VAL848
3.598
ALA866
3.358
VAL867
3.991
LYS868
3.419
GLU885
2.737
ILE888
3.869
LEU889
3.490
ILE892
3.783
VAL898
4.241
VAL899
3.357
VAL914
3.352
ILE915
4.886
VAL916
3.546
GLU917
3.241
|
|||||
| Ligand Name: 2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxy-phenyl]-~{N}-(1-propan-2-ylpyrazol-4-yl)ethanamide | Ligand Info | |||||
| Structure Description | Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 18) | PDB:6GQO | ||||
| Method | X-ray diffraction | Resolution | 1.87 Å | Mutation | No | [12] |
| PDB Sequence |
LPLDEHCERL
820 PYDASKWEFP830 RDRLKLGKPL840 GRGAFGQVIE850 ADAFGIDKTA860 TCRTVAVKML 870 KEGATHSEHR880 ALMSELKILI890 HIGHHLNVVN900 LLGACTKPGG910 PLMVIVEFCK 920 FGNLSTYLRS930 KRNEFVPYKV940 APEDLYKDFL1000 TLEHLICYSF1010 QVAKGMEFLA 1020 SRKCIHRDLA1030 ARNILLSEKN1040 VVKICDFGLA1050 RDIYKDPDYV1060 RKGDARLPLK 1070 WMAPETIFDR1080 VYTIQSDVWS1090 FGVLLWEIFS1100 LGASPYPGVK1110 IDEEFCRRLK 1120 EGTRMRAPDY1130 TTPEMYQTML1140 DCWHGEPSQR1150 PTFSELVEHL1160 GNLLQANA |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .F82 or .F822 or .F823 or :3F82;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.445
GLY841
4.565
VAL848
3.552
ALA866
3.352
VAL867
3.681
LYS868
3.271
GLU885
2.710
ILE888
4.519
LEU889
3.659
ILE892
3.841
VAL898
3.368
VAL899
3.353
VAL914
3.488
ILE915
4.919
|
|||||
| Ligand Name: N-(4,4-dimethyl-2-prop-1-ynyl-3,1-benzoxazin-6-yl)-2-[3-methoxy-5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]acetamide | Ligand Info | |||||
| Structure Description | Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor bearing an acrylamide | PDB:6XVK | ||||
| Method | X-ray diffraction | Resolution | 1.99 Å | Mutation | Yes | [13] |
| PDB Sequence |
PYDASKWEFP
830 RDRLKLGKPL840 GRGAFGQVIE850 ADAFGIDKTA860 TCRTVAVKML870 KEGATHSEHR 880 ALMSELKILI890 HIGHHLNVVN900 LLGACTKPGG910 PLMVIVEFCK920 FGNLSTYLRS 930 KRNEFVPYKV990 APEDLYKDFL1000 TLEHLICYSF1010 QVAKGMEFLA1020 SRKCIHRDLA 1030 ARNILLSEKN1040 VVKICDFGLA1050 RDIYKDPDYV1060 RKGDARLPLK1070 WMAPETIFDR 1080 VYTIQSDVWS1090 FGVLLWEIFS1100 LGASPYPGVK1110 IDEEFCRRLK1120 EGTRMRAPDY 1130 TTPEMYQTML1140 DCWHGEPSQR1150 PTFSELVEHL1160 GNLLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .O3E or .O3E2 or .O3E3 or :3O3E;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1016 or .A:1019 or .A:1020 or .A:1024 or .A:1025 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047 or .A:1084 or .A:1087; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.621
VAL848
3.517
ALA866
3.436
VAL867
3.944
LYS868
3.373
GLU885
2.797
ILE888
3.398
LEU889
3.899
ILE892
4.235
VAL898
4.396
VAL899
2.826
VAL914
3.230
ILE915
4.825
VAL916
3.435
GLU917
3.248
PHE918
3.788
CYS919
2.894
|
|||||
| Ligand Name: N-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(1-ethylpyrazol-4-yl)acetamide | Ligand Info | |||||
| Structure Description | Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 23) | PDB:6GQP | ||||
| Method | X-ray diffraction | Resolution | 2.09 Å | Mutation | No | [12] |
| PDB Sequence |
PYDASKWEFP
830 RDRLKLGKPL840 GRGAFGQVIE850 ADAFGIDKTA860 TCRTVAVKML870 KEGATHSEHR 880 ALMSELKILI890 HIGHHLNVVN900 LLGACTKPGG910 PLMVIVEFCK920 FGNLSTYLRS 930 KRNEFVPYKV940 APEDLYKDFL1000 TLEHLICYSF1010 QVAKGMEFLA1020 SRKCIHRDLA 1030 ARNILLSEKN1040 VVKICDFGLA1050 RDIYKDPDYV1060 RKGDARLPLK1070 WMAPETIFDR 1080 VYTIQSDVWS1090 FGVLLWEIFS1100 LGASPYPGVK1110 IDEEFCRRLK1120 EGTRMRAPDY 1130 TTPEMYQTML1140 DCWHGEPSQR1150 PTFSELVEHL1160 GNLLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .F88 or .F882 or .F883 or :3F88;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.573
GLY841
4.148
VAL848
3.439
ALA866
3.482
LYS868
3.479
GLU885
3.215
ILE888
4.872
LEU889
3.760
ILE892
4.894
VAL898
3.843
VAL899
3.332
VAL916
3.582
GLU917
3.267
|
|||||
| Ligand Name: N-[3-({2-[(Cyclopropylcarbonyl)amino]imidazo[1,2-B]pyridazin-6-Yl}oxy)phenyl]-1,3-Dimethyl-1h-Pyrazole-5-Carboxamide | Ligand Info | |||||
| Structure Description | Crystal Structure of the Kinase domain of Human VEGFR2 with imidazo[1,2-b]pyridazine derivative | PDB:3VO3 | ||||
| Method | X-ray diffraction | Resolution | 1.52 Å | Mutation | No | [14] |
| PDB Sequence |
PLDEHCERLP
821 YDASKWEFPR831 DRLKLGKPLG841 RGAFGQVIEA851 DAFGIDKTAT861 CRTVAVKMLK 871 EGATHSEHRA881 LMSELKILIH891 IGHHLNVVNL901 LGACTKPGGP911 LMVIVEFCKF 921 GNLSTYLRSK931 RNEFVPYKDL995 YKDFLTLEHL1005 ICYSFQVAKG1015 MEFLASRKCI 1025 HRDLAARNIL1035 LSEKNVVKIC1045 DFGLARDIYK1055 DPDYVRKGDA1065 RLPLKWMAPE 1075 TIFDRVYTIQ1085 SDVWSFGVLL1095 WEIFSLGASP1105 YPGVKIDEEF1115 CRRLKEGTRM 1125 RAPDYTTPEM1135 YQTMLDCWHG1145 EPSQRPTFSE1155 LVEHLGNLLQ1165 ANA |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .0KF or .0KF2 or .0KF3 or :30KF;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.688
VAL848
3.620
ALA866
3.428
VAL867
4.667
LYS868
3.459
GLU885
2.763
ILE888
3.572
LEU889
3.530
ILE892
4.413
VAL898
3.864
VAL899
3.916
VAL914
3.884
|
|||||
| Ligand Name: 2-Chloro-3-(1-Cyanocyclopropyl)-N-[5-({2-[(Cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-B]pyridin-5-Yl}oxy)-2-Fluorophenyl]benzamide | Ligand Info | |||||
| Structure Description | Crystal Structure of the Kinase domain of Human VEGFR2 with a [1,3]thiazolo[5,4-b]pyridine derivative | PDB:3VNT | ||||
| Method | X-ray diffraction | Resolution | 1.64 Å | Mutation | No | [15] |
| PDB Sequence |
PLDEHCERLP
821 YDASKWEFPR831 DRLKLGKPLG841 RGAFGQVIEA851 DAFGIDKTAT861 CRTVAVKMLK 871 EGATHSEHRA881 LMSELKILIH891 IGHHLNVVNL901 LGACTKPGGP911 LMVIVEFCKF 921 GNLSTYLRSK931 RNEFVPYKYK997 DFLTLEHLIC1007 YSFQVAKGME1017 FLASRKCIHR 1027 DLAARNILLS1037 EKNVVKICDF1047 GLARDIYKDP1057 DYVRKGDARL1067 PLKWMAPETI 1077 FDRVYTIQSD1087 VWSFGVLLWE1097 IFSLGASPYP1107 GVKIDEEFCR1117 RLKEGTRMRA 1127 PDYTTPEMYQ1137 TMLDCWHGEP1147 SQRPTFSELV1157 EHLGNLLQAN1167 A |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .0JA or .0JA2 or .0JA3 or :30JA;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.726
VAL848
3.550
ALA866
3.423
VAL867
4.635
LYS868
3.451
GLU885
2.919
ILE888
4.714
LEU889
3.552
ILE892
3.230
VAL898
3.399
VAL899
3.325
VAL914
3.299
VAL916
3.323
|
|||||
| Ligand Name: N-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-D]pyrimidin-5-YL]phenyl}-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea | Ligand Info | |||||
| Structure Description | Vegfr2 in complex with a novel 4-amino-furo[2,3-d]pyrimidine | PDB:1YWN | ||||
| Method | X-ray diffraction | Resolution | 1.71 Å | Mutation | Yes | [5] |
| PDB Sequence |
LPYDASKWEF
827 PRDRLKLGKP837 LGRGAFGQVI847 EADAFGIDKT857 ATCRTVAVKM867 LTHSEHRALM 881 SELKILIHIG891 HHLNVVNLLG901 ACTKPGGPLM911 VIVEFCKFGN921 LSTYLRSKRN 931 EFVPFLTLEH1002 LICYSFQVAK1012 GMEFLASRKC1022 IHRDLAARNI1032 LLSEKNVVKI 1042 CDIKDPDVRK1060 GDARLPLKWM1070 APETIFDRVY1080 TIQSDVWSFG1090 VLLWEIFSLG 1100 ASPYPGVKID1110 EEFCRRLKEG1120 TRMRAPDYTT1130 PEMYQTMLDC1140 WHGEPSQRPT 1150 FSELVEHLGN1160 LLQANAQQD
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .LIF or .LIF2 or .LIF3 or :3LIF;style chemicals stick;color identity;select .A:838 or .A:839 or .A:840 or .A:841 or .A:844 or .A:846 or .A:864 or .A:866 or .A:883 or .A:886 or .A:887 or .A:890 or .A:896 or .A:897 or .A:914 or .A:915 or .A:916 or .A:917 or .A:1017 or .A:1024 or .A:1033 or .A:1042 or .A:1043 or .A:1044; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU838
3.641
GLY839
3.663
ARG840
3.408
GLY841
3.237
GLY844
4.504
VAL846
3.536
ALA864
3.685
LYS866
4.296
GLU883
2.835
ILE886
3.954
LEU887
3.864
ILE890
3.703
|
|||||
| Ligand Name: Methyl (5-{4-[({[2-Fluoro-5-(Trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-1h-Benzimidazol-2-Yl)carbamate | Ligand Info | |||||
| Structure Description | Crystal structure of Vegfr2 with a benzimidazole-urea inhibitor | PDB:2OH4 | ||||
| Method | X-ray diffraction | Resolution | 2.05 Å | Mutation | No | [16] |
| PDB Sequence |
HCERLPYDAS
823 KWEFPRDRLN833 LGKPLGRGAF843 GQVIEADAFG853 IDKTATCRTV863 AVKMLKEGAT 873 HSEHRALMSE883 LKILIHIGHH893 LNVVNLLGAC903 TKPGGPLMVI913 VEFCKFGNLS 923 TYLRSKRNEF933 VPYYKDFLTL1000 EHLICYSFQV1010 AKGMEFLASR1020 KCIHRDLAAR 1030 NILLSEKNVV1040 KICDFGLARD1050 IKDPDVRKGD1062 ARLPLKWMAP1072 ETIFDRVYTI 1082 QSDVWSFGVL1092 LWEIFSLGAS1102 PYPGVKIDEE1112 FCRRLKEGTR1122 MRAPDYTTPE 1132 MYQTMLDCWH1142 GEPSQRPTFS1152 ELVEHLGNLL1162 QANAQQD
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .GIG or .GIG2 or .GIG3 or :3GIG;style chemicals stick;color identity;select .A:838 or .A:846 or .A:864 or .A:866 or .A:883 or .A:886 or .A:887 or .A:890 or .A:896 or .A:897 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:1017 or .A:1024 or .A:1033 or .A:1042 or .A:1043 or .A:1044 or .A:1045; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU838
3.594
VAL846
3.444
ALA864
3.418
LYS866
3.953
GLU883
2.814
ILE886
3.931
LEU887
3.744
ILE890
3.982
VAL896
3.594
VAL897
3.426
VAL914
3.604
GLU915
3.189
|
|||||
| Ligand Name: N-[4-({3-[2-(methylamino)pyrimidin-4-yl]pyridin-2-yl}oxy)naphthalen-1-yl]-6-(trifluoromethyl)-1H-benzimidazol-2-amine | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a pyridyl-pyrimidine benzimidazole inhibitor | PDB:3EWH | ||||
| Method | X-ray diffraction | Resolution | 1.60 Å | Mutation | Yes | [17] |
| PDB Sequence |
EHAERLPYDA
824 SKWEFPRDRL834 KLGKPLGRGA844 FGQVIEADAF854 GIDTCRTVAV867 KMLKEGATHS 877 EHRALMSELK887 ILIHIGHHLN897 VVNLLGACTK907 PGGPLMVITE917 FCKFGNLSTY 927 LRSKRNEFVP937 YKVAPEDLYK997 DFLTLEHLIC1007 YSFQVAKGME1017 FLASRKCIHR 1027 DLAARNILLS1037 EKNVVKICDF1047 GLARDPDYVR1061 LPLKWMAPET1076 IFDRVYTIQS 1086 DVWSFGVLLW1096 EIFSLGASPY1106 PGVKIDEEFC1116 RRLKEGTRMR1126 APDYTTPEMY 1136 QTMLDCWHGE1146 PSQRPTFSEL1156 VEHLGNLLQA1166 NAQQDRHHHH1176 |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .K11 or .K112 or .K113 or :3K11;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.660
GLY841
4.274
VAL848
3.584
ALA866
3.481
VAL867
4.686
LYS868
3.572
GLU885
2.625
ILE888
4.477
LEU889
3.785
ILE892
3.569
VAL898
3.181
VAL899
3.920
VAL914
3.759
|
|||||
| Ligand Name: N-{3-[3-(Dimethylamino)propyl]-5-(Trifluoromethyl)phenyl}-4-Methyl-3-[(3-Pyrimidin-4-Ylpyridin-2-Yl)amino]benzamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a benzamide inhibitor | PDB:3BE2 | ||||
| Method | X-ray diffraction | Resolution | 1.75 Å | Mutation | Yes | [18] |
| PDB Sequence |
EHAERLPYDA
824 SKWEFPRDRL834 KLGKPLGRGA844 FGQVIEADAF854 GIDTCRTVAV867 KMLKEGATHS 877 EHRALMSELK887 ILIHIGHHLN897 VVNLLGACTK907 PGGPLMVITE917 FCKFGNLSTY 927 LRSKRNEFVP937 YKVAPEDLYK997 DFLTLEHLIC1007 YSFQVAKGME1017 FLASRKCIHR 1027 DLAARNILLS1037 EKNVVKICDF1047 GPLKWMAPET1076 IFDRVYTIQS1086 DVWSFGVLLW 1096 EIFSLGASPY1106 PGVKIDEEFC1116 RRLKEGTRMR1126 APDYTTPEMY1136 QTMLDCWHGE 1146 PSQRPTFSEL1156 VEHLGNLLQA1166 NAQQDRHHHH1176
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .RAJ or .RAJ2 or .RAJ3 or :3RAJ;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047 or .A:1048; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.780
GLY841
4.838
VAL848
3.534
ALA866
3.330
VAL867
4.244
LYS868
3.870
GLU885
2.881
ILE888
4.436
LEU889
3.896
ILE892
4.029
VAL898
3.692
VAL899
3.695
VAL914
4.120
|
|||||
| Ligand Name: 4-(2-Anilinopyridin-3-Yl)-N-(3,4,5-Trimethoxyphenyl)-1,3,5-Triazin-2-Amine | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a pyridinyl-triazine inhibitor | PDB:2P2H | ||||
| Method | X-ray diffraction | Resolution | 1.95 Å | Mutation | Yes | [19] |
| PDB Sequence |
EHAERLPYDA
824 SKWEFPRDRL834 KLGKPLGRQV848 IEADAFGIDK858 TATCRTVAVK868 MLKEGATHSE 878 HRALMSELKI888 LIHIGHHLNV898 VNLLGACTKP908 GGPLMVITEF918 CKFGNLSTYL 928 RSKRNEFVPY938 KVAPEDLYKD998 FLTLEHLICY1008 SFQVAKGMEF1018 LASRKCIHRD 1028 LAARNILLSE1038 KNVVKICDFG1048 LARLPLKWMA1073 PETIFDRVYT1083 IQSDVWSFGV 1093 LLWEIFSLGA1103 SPYPGVKIDE1113 EFCRRLKEGT1123 RMRAPDYTTP1133 EMYQTMLDCW 1143 HGEPSQRPTF1153 SELVEHLGNL1163 LQANAQQDRH1173 HH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .994 or .9942 or .9943 or :3994;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:889 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:923 or .A:1035 or .A:1045 or .A:1046; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.952
VAL848
3.493
ALA866
3.517
VAL867
4.976
LYS868
3.561
GLU885
3.391
LEU889
3.993
VAL899
4.029
VAL914
4.042
THR916
3.374
|
|||||
| Ligand Name: 4-({2-[(4-chloro-3-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}phenyl)amino]-1,3-benzoxazol-5-yl}oxy)-N-methylpyridine-2-carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a benzoxazole inhibitor | PDB:2QU6 | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | Yes | [20] |
| PDB Sequence |
AERLPYDASK
826 WEFPRDRLKL836 GKPLGQVIEA851 DAFGIDKTCR863 TVAVKMLKTH876 SEHRALMSEL 886 KILIHIGHHL896 NVVNLLGACT906 KPGGPLMVIT916 EFCKFGNLST926 YLRSKRNEFV 936 PYKVAPEDLY996 KDFLTLEHLI1006 CYSFQVAKGM1016 EFLASRKCIH1026 RDLAARNILL 1036 SEKNVVKICD1046 FGPLKWMAPE1075 TIFDRVYTIQ1085 SDVWSFGVLL1095 WEIFSLGASP 1105 YPGVKIDEEF1115 CRRLKEGTRM1125 RAPDYTTPEM1135 YQTMLDCWHG1145 EPSQRPTFSE 1155 LVEHLGNLLQ1165 ANAQQDRHHH1175 HHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .857 or .8572 or .8573 or :3857;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1024 or .A:1025 or .A:1026 or .A:1027 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.712
VAL848
3.291
ALA866
3.437
VAL867
4.659
LYS868
3.819
GLU885
2.935
ILE888
3.982
LEU889
3.894
ILE892
4.790
VAL898
4.144
VAL899
3.565
VAL914
4.727
THR916
3.537
GLU917
3.078
PHE918
3.522
|
|||||
| Ligand Name: N-{4-[(6,7-Dimethoxyquinolin-4-Yl)oxy]-3-Fluorophenyl}-1,5-Dimethyl-3-Oxo-2-Phenyl-2,3-Dihydro-1h-Pyrazole-4-Carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a pyrazolone inhibitor | PDB:3U6J | ||||
| Method | X-ray diffraction | Resolution | 2.15 Å | Mutation | Yes | [21] |
| PDB Sequence |
EHCERLPYDA
824 SKWEFPRDRL834 KLGKPLGRGA844 FGQVIEADAF854 GIDATCRTVA866 VKMLKEGATH 876 SEHRALMSEL886 KILIHIGHHL896 NVVNLLGACT906 KPGGPLMVIT916 EFCKFGNLST 926 YLRSKRNEFV936 PYKVAPEDLY996 KDFLTLEHLI1006 CYSFQVAKGM1016 EFLASRKCIH 1026 RDLAARNILL1036 SEKNVVKICD1046 FGLARDIYKD1056 PDYVRKGDAR1066 LPLKWMAPET 1076 IFDRVYTIQS1086 DVWSFGVLLW1096 EIFSLGASPY1106 PGVKIDEEFC1116 RRLKEGTRMR 1126 APDYTTPEMY1136 QTMLDCWHGE1146 PSQRPTFSEL1156 VEHLGNLLQA1166 NAQQDRHH |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .03X or .03X2 or .03X3 or :303X;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:886 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.597
GLY841
3.925
VAL848
3.368
ALA866
3.453
VAL867
4.811
LYS868
2.856
GLU885
3.355
LEU886
4.717
ILE888
3.583
LEU889
3.592
ILE892
3.965
VAL898
3.703
VAL899
4.454
THR916
3.662
|
|||||
| Ligand Name: 3-(2-Aminoquinazolin-6-Yl)-4-Methyl-1-[3-(Trifluoromethyl)phenyl]pyridin-2(1h)-One | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a pyridone inhibitor | PDB:3CPC | ||||
| Method | X-ray diffraction | Resolution | 2.40 Å | Mutation | Yes | [22] |
| PDB Sequence |
LPYDASKWEF
829 PRDRLKLGKP839 LQVIEADAFG855 IDKTATCRTV865 AVKMLKEGAT875 HSEHRALMSE 885 LKILIHIGHH895 LNVVNLLGAC905 TKPGGPLMVI915 TEFCKFGNLS925 TYLRSKRNEF 935 VPYKVAPEDL995 YKDFLTLEHL1005 ICYSFQVAKG1015 MEFLASRKCI1025 HRDLAARNIL 1035 LSEKNVVKIC1045 DFLPLKWMAP1074 ETIFDRVYTI1084 QSDVWSFGVL1094 LWEIFSLGAS 1104 PYPGVKIDEE1114 FCRRLKEGTR1124 MRAPDYTTPE1134 MYQTMLDCWH1144 GEPSQRPTFS 1154 ELVEHLGNLL1164 QANAQQDRHH1174 HHHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .C52 or .C522 or .C523 or :3C52;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
4.338
VAL848
3.706
ALA866
3.538
VAL867
4.047
LYS868
3.726
GLU885
3.396
LEU889
3.452
ILE892
4.593
VAL898
3.370
VAL899
3.531
VAL914
4.116
THR916
3.230
|
|||||
| Ligand Name: N-(4-Phenoxyphenyl)-2-[(Pyridin-4-Ylmethyl)amino]nicotinamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a nicotinamide inhibitor | PDB:2P2I | ||||
| Method | X-ray diffraction | Resolution | 2.40 Å | Mutation | Yes | [19] |
| PDB Sequence |
AERLPYDASK
826 WEFPRDRLKL836 GKPLGRGAFG846 QVIEADAFGI856 DTCRTVAVKM869 LTHSEHRALM 883 SELKILIHIG893 HHLNVVNLLG903 ACTKPGGPLM913 VIVEFCKFGN923 LSTYLRSKRN 933 EFVPYKVAPE993 DLYKDFLTLE1003 HLICYSFQVA1013 KGMEFLASRK1023 CIHRDLAARN 1033 ILLSEKNVVK1043 ICDFGLALPL1069 KWMAPETIFD1079 RVYTIQSDVW1089 SFGVLLWEIF 1099 SLGASPYPGV1109 KIDEEFCRRL1119 KEGTRMRAPD1129 YTTPEMYQTM1139 LDCWHGEPSQ 1149 RPTFSELVEH1159 LGNLLQANAQ1169 QDRHHHHHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .608 or .6082 or .6083 or :3608;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:1019 or .A:1024 or .A:1025 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047 or .A:1050; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.497
VAL848
3.563
ALA866
3.543
VAL867
3.859
LYS868
3.652
GLU885
2.870
ILE888
3.537
LEU889
3.774
ILE892
3.444
VAL898
4.295
VAL899
4.154
VAL914
3.589
ILE915
4.978
VAL916
3.703
|
|||||
| Ligand Name: 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a pyridone inhibitor | PDB:3CP9 | ||||
| Method | X-ray diffraction | Resolution | 2.50 Å | Mutation | Yes | [22] |
| PDB Sequence |
AERLPYDASK
826 WEFPRDRLKL836 GKPLQVIEAD852 AFGIDKTATC862 RTVAVKMLKE872 GATHSEHRAL 882 MSELKILIHI892 GHHLNVVNLL902 GACTKPGGPL912 MVITEFCKFG922 NLSTYLRSKR 932 NEFVPYKVAP992 EDLYKDFLTL1002 EHLICYSFQV1012 AKGMEFLASR1022 KCIHRDLAAR 1032 NILLSEKNVV1042 KICDFGLPLK1070 WMAPETIFDR1080 VYTIQSDVWS1090 FGVLLWEIFS 1100 LGASPYPGVK1110 IDEEFCRRLK1120 EGTRMRAPDY1130 TTPEMYQTML1140 DCWHGEPSQR 1150 PTFSELVEHL1160 GNLLQANAQQ1170 DRHHHHHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .C19 or .C192 or .C193 or :3C19;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:922 or .A:1019 or .A:1024 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.694
VAL848
3.545
ALA866
3.663
VAL867
3.879
LYS868
3.663
GLU885
3.199
ILE888
4.385
LEU889
3.650
ILE892
3.879
VAL898
3.229
VAL899
3.936
VAL914
4.205
THR916
3.447
|
|||||
| Ligand Name: N-(4-Chlorophenyl)-7-[(6,7-Dimethoxyquinolin-4-Yl)oxy]-2,3-Dihydro-1,4-Benzoxazine-4-Carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a 2,3-dihydro-1,4-benzoxazine inhibitor | PDB:2RL5 | ||||
| Method | X-ray diffraction | Resolution | 2.65 Å | Mutation | Yes | [23] |
| PDB Sequence |
EHAERLPYDA
824 SKWEFPRDRL834 KLGKPLGRGQ847 VIEADAFGID857 KTATCRTVAV867 KMLKEGATHS 877 EHRALMSELK887 ILIHIGHHLN897 VVNLLGACTK907 PGGPLMVITE917 FCKFGNLSTY 927 LRSKRNEFVP937 YKVAPEDLYK997 DFLTLEHLIC1007 YSFQVAKGME1017 FLASRKCIHR 1027 DLAARNILLS1037 EKNVVKICDF1047 GLDARLPLKW1071 MAPETIFDRV1081 YTIQSDVWSF 1091 GVLLWEIFSL1101 GASPYPGVKI1111 DEEFCRRLKE1121 GTRMRAPDYT1131 TPEMYQTMLD 1141 CWHGEPSQRP1151 TFSELVEHLG1161 NLLQANAQQD1171 RHHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .2RL or .2RL2 or .2RL3 or :32RL;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.340
GLY841
4.957
VAL848
3.350
ALA866
3.478
LYS868
3.872
GLU885
2.977
ILE888
4.824
LEU889
3.674
ILE892
3.783
VAL898
4.542
VAL899
3.673
VAL914
4.078
THR916
3.557
|
|||||
| Ligand Name: N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a bisamide inhibitor | PDB:3CPB | ||||
| Method | X-ray diffraction | Resolution | 2.70 Å | Mutation | Yes | [22] |
| PDB Sequence |
RLPYDASKWE
828 FPRDRLKLGK838 PLQVIEADAF854 GIDKTATCRT864 VAVKMLKEGA874 THSEHRALMS 884 ELKILIHIGH894 HLNVVNLLGA904 CTKPGGPLMV914 ITEFCKFGNL924 STYLRSKRNE 934 FVPYKVAPED994 LYKDFLTLEH1004 LICYSFQVAK1014 GMEFLASRKC1024 IHRDLAARNI 1034 LLSEKNVVKI1044 CDFLPLKWMA1073 PETIFDRVYT1083 IQSDVWSFGV1093 LLWEIFSLGA 1103 SPYPGVKIDE1113 EFCRRLKEGT1123 RMRAPDYTTP1133 EMYQTMLDCW1143 HGEPSQRPTF 1153 SELVEHLGNL1163 LQANAQQDRH1173 HHHHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .C92 or .C922 or .C923 or :3C92;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:922 or .A:1019 or .A:1024 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.961
VAL848
3.511
ALA866
3.472
VAL867
3.960
LYS868
3.633
GLU885
2.635
ILE888
3.851
LEU889
3.913
ILE892
4.414
VAL898
3.676
VAL899
3.663
VAL914
3.581
ILE915
4.916
|
|||||
| Ligand Name: N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a naphthamide inhibitor | PDB:3B8R | ||||
| Method | X-ray diffraction | Resolution | 2.70 Å | Mutation | Yes | [24] |
| PDB Sequence |
ERLPYDASKW
827 EFPRDRLKLG837 KPLGQVIEAD852 AFGIDKTATC862 RTVAVKMLKE872 GATHSEHRAL 882 MSELKILIHI892 GHHLNVVNLL902 GACTKPGGPL912 MVITEFCKFG922 NLSTYLRSKR 932 NEFVPYKVAP992 EDLYKDFLTL1002 EHLICYSFQV1012 AKGMEFLASR1022 KCIHRDLAAR 1032 NILLSEKNVV1042 KICDFGLLPL1069 KWMAPETIFD1079 RVYTIQSDVW1089 SFGVLLWEIF 1099 SLGASPYPGV1109 KIDEEFCRRL1119 KEGTRMRAPD1129 YTTPEMYQTM1139 LDCWHGEPSQ 1149 RPTFSELVEH1159 LGNLLQANAQ1169 QDRHHHHHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .887 or .8872 or .8873 or :3887;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:868 or .A:885 or .A:888 or .A:889 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1035 or .A:1045 or .A:1046 or .A:1047 or .A:1049; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.126
GLY841
4.441
VAL848
3.386
ALA866
3.464
LYS868
3.528
GLU885
3.255
ILE888
3.979
LEU889
3.568
VAL899
3.799
VAL914
3.524
THR916
3.596
|
|||||
| Ligand Name: N-(4-chlorophenyl)-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a naphthamide inhibitor | PDB:3B8Q | ||||
| Method | X-ray diffraction | Resolution | 2.75 Å | Mutation | Yes | [18] |
| PDB Sequence |
ERLPYDASKW
827 EFPRDRLKLG837 KPLGRGAFGQ847 VIEADAFGID857 KTATCRTVAV867 KMLKEGATHS 877 EHRALMSELK887 ILIHIGHHLN897 VVNLLGACTK907 PGGPLMVITE917 FCKFGNLSTY 927 LRSKRNEFVP937 YKVAPEDLYK997 DFLTLEHLIC1007 YSFQVAKGME1017 FLASRKCIHR 1027 DLAARNILLS1037 EKNVVKICDF1047 LPLKWMAPET1076 IFDRVYTIQS1086 DVWSFGVLLW 1096 EIFSLGASPY1106 PGVKIDEEFC1116 RRLKEGTRMR1126 APDYTTPEMY1136 QTMLDCWHGE 1146 PSQRPTFSEL1156 VEHLGNLLQA1166 NAQQDRHHHH1176 HH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .900 or .9002 or .9003 or :3900;style chemicals stick;color identity;select .A:840 or .A:841 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:923 or .A:1019 or .A:1024 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.017
GLY841
4.567
VAL848
3.228
ALA866
3.353
VAL867
4.913
LYS868
3.380
GLU885
3.212
ILE888
4.971
LEU889
3.555
ILE892
4.026
VAL898
4.774
VAL899
3.528
VAL914
3.673
THR916
3.512
GLU917
3.319
|
|||||
| Ligand Name: 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a benzisoxazole inhibitor | PDB:3DTW | ||||
| Method | X-ray diffraction | Resolution | 2.90 Å | Mutation | Yes | [25] |
| PDB Sequence |
ERLPYDASKW
827 EFPRDRLKLG837 KPLGRGGQVI849 EADAFGIDKT861 CRTVAVKMLK871 EGATHSEHRA 881 LMSELKILIH891 IGHHLNVVNL901 LGACTKPGGP911 LMVITEFCKF921 GNLSTYLRSK 931 RNEFVPYKVA991 PEDLYKDFLT1001 LEHLICYSFQ1011 VAKGMEFLAS1021 RKCIHRDLAA 1031 RNILLSEKNV1041 VKICDFLPLK1070 WMAPETIFDR1080 VYTIQSDVWS1090 FGVLLWEIFS 1100 LGASPYPGVK1110 IDEEFCRRLK1120 EGTRMRAPDY1130 TTPEMYQTML1140 DCWHGEPSQR 1150 PTFSELVEHL1160 GNLLQANAQQ1170 DRHHHHHH
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .A96 or .A962 or .A963 or :3A96;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:1019 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.656
VAL848
3.777
ALA866
3.281
VAL867
3.721
LYS868
3.418
GLU885
3.304
ILE888
4.447
LEU889
3.178
ILE892
3.496
VAL898
3.436
VAL899
3.817
VAL914
3.759
|
|||||
| Ligand Name: 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of the VEGFR2 kinase domain in complex with a benzimidazole inhibitor | PDB:2QU5 | ||||
| Method | X-ray diffraction | Resolution | 2.95 Å | Mutation | Yes | [20] |
| PDB Sequence |
HAERLPYDAS
825 KWEFPRDRLK835 LGKPLGRGAF845 GQVIEADAFG855 IDKTATCRTV865 AVKMLKEGAT 875 HSEHRALMSE885 LKILIHIGHH895 LNVVNLLGAC905 TKPGGPLMVI915 TEFCKFGNLS 925 TYLRSKRNEF935 VPYKVAPEDL995 YKDFLTLEHL1005 ICYSFQVAKG1015 MEFLASRKCI 1025 HRDLAARNIL1035 LSEKNVVKIC1045 DFGLADARLP1068 LKWMAPETIF1078 DRVYTIQSDV 1088 WSFGVLLWEI1098 FSLGASPYPG1108 VKIDEEFCRR1118 LKEGTRMRAP1128 DYTTPEMYQT 1138 MLDCWHGEPS1148 QRPTFSELVE1158 HLGNLLQANA1168 QQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .276 or .2762 or .2763 or :3276;style chemicals stick;color identity;select .A:840 or .A:848 or .A:866 or .A:867 or .A:868 or .A:885 or .A:888 or .A:889 or .A:892 or .A:898 or .A:899 or .A:914 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:922 or .A:1019 or .A:1025 or .A:1026 or .A:1035 or .A:1044 or .A:1045 or .A:1046 or .A:1047; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU840
3.715
VAL848
3.240
ALA866
3.335
VAL867
4.554
LYS868
3.738
GLU885
2.857
ILE888
3.567
LEU889
3.771
ILE892
3.340
VAL898
3.790
VAL899
3.548
VAL914
4.729
THR916
3.453
GLU917
3.335
|
|||||
| Ligand Name: N~4~-(3-Methyl-1h-Indazol-6-Yl)-N~2~-(3,4,5-Trimethoxyphenyl)pyrimidine-2,4-Diamine | Ligand Info | |||||
| Structure Description | Crystal structure of VEGFR2 in complex with a 3,4,5-trimethoxy aniline containing pyrimidine | PDB:3CJF | ||||
| Method | X-ray diffraction | Resolution | 2.15 Å | Mutation | No | [8] |
| PDB Sequence |
CERLPYDASK
824 WEFPRDRLNL834 GKPLGRGAFG844 QVIEADAFGI854 DKTATRTVAV865 KMLKEGATHS 875 EHRALMSELK885 ILIHIGHHLN895 VVNLLGACTK905 PGGPLMVIVE915 FCKFGNLSTY 925 LRSKRNEFVP935 YKKDFLTLEH1002 LIYSFQVAKG1013 MEFLASRKIH1024 RDLAARNILL 1034 SEKNVVKIDL1047 ARDIYKPLKW1069 MAPETIFDRV1079 YTIQSDVWSF1089 GVLLWEIFSL 1099 GASPYPGVKI1109 DEEFRRLKEG1120 TRMRAPDYTT1130 PEMYQTMLDC1140 WHGEPSQRPT 1150 FSELVEHLGN1160 LLQANA
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .SAV or .SAV2 or .SAV3 or :3SAV;style chemicals stick;color identity;select .A:838 or .A:839 or .A:846 or .A:864 or .A:897 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:1033; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: N~4~-Methyl-N~4~-(3-Methyl-1h-Indazol-6-Yl)-N~2~-(3,4,5-Trimethoxyphenyl)pyrimidine-2,4-Diamine | Ligand Info | |||||
| Structure Description | Crystal structure of VEGFR2 in complex with a 3,4,5-trimethoxy aniline containing pyrimidine | PDB:3CJG | ||||
| Method | X-ray diffraction | Resolution | 2.25 Å | Mutation | No | [8] |
| PDB Sequence |
HCERLPYDAS
823 KWEFPRDRLN833 LGKPLGRGQV846 IEADAFGIDK856 TATRTVAVKM867 LKEGATHSEH 877 RALMSELKIL887 IHIGHHLNVV897 NLLGACTKPG907 GPLMVIVEFC917 KFGNLSTYLR 927 SKRNEFVPYK937 DLYKDFLTLE1001 HLICYSFQVA1011 KGMEFLASRK1021 IHRDLAARNI 1032 LLSEKNVVKI1042 CDFGLARDIP1066 LKWMAPETIF1076 DRVYTIQSDV1086 WSFGVLLWEI 1096 FSLGASPYPG1106 VKIDEEFCRR1116 LKEGTRMRAP1126 DYTTPEMYQT1136 MLDCWHGEPS 1146 QRPTFSELVE1156 HLGNLLQANA1166
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .KIM or .KIM2 or .KIM3 or :3KIM;style chemicals stick;color identity;select .A:838 or .A:846 or .A:864 or .A:865 or .A:866 or .A:880 or .A:883 or .A:887 or .A:897 or .A:912 or .A:914 or .A:915 or .A:916 or .A:917 or .A:918 or .A:919 or .A:920 or .A:921 or .A:1033 or .A:1044; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
LEU838
3.536
VAL846
3.650
ALA864
3.736
VAL865
4.954
LYS866
3.310
LEU880
4.603
GLU883
2.701
LEU887
4.794
VAL897
4.298
VAL912
3.800
|
|||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18281-9. | ||||
| REF 2 | BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. | ||||
| REF 3 | Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett. 2014 Nov 17;6(1):89-94. | ||||
| REF 4 | Discovery of the Selective Vegfr Inhibitor Pf- 00337210 | ||||
| REF 5 | Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett. 2005 May 2;15(9):2203-7. | ||||
| REF 6 | A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. J Med Chem. 2016 Jan 14;59(1):132-46. | ||||
| REF 7 | Discovery of Motesanib | ||||
| REF 8 | Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008 Aug 14;51(15):4632-40. | ||||
| REF 9 | A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases. ACS Med Chem Lett. 2012 Feb 28;3(4):342-6. | ||||
| REF 10 | Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. | ||||
| REF 11 | Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg Med Chem. 2010 Oct 15;18(20):7260-73. | ||||
| REF 12 | Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J Med Chem. 2018 Oct 11;61(19):8797-8810. | ||||
| REF 13 | Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors. J Am Chem Soc. 2020 Jun 10;142(23):10358-10372. | ||||
| REF 14 | Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor. Bioorg Med Chem. 2013 Apr 15;21(8):2333-2345. | ||||
| REF 15 | Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. J Med Chem. 2012 Apr 12;55(7):3452-78. | ||||
| REF 16 | Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem. 2007 Sep 6;50(18):4453-70. | ||||
| REF 17 | Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase. Bioorg Med Chem Lett. 2009 Jan 15;19(2):424-7. | ||||
| REF 18 | Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J Med Chem. 2008 Mar 27;51(6):1649-67. | ||||
| REF 19 | Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. J Med Chem. 2007 Feb 22;50(4):611-26. | ||||
| REF 20 | Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J Med Chem. 2007 Sep 6;50(18):4351-73. | ||||
| REF 21 | Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. J Med Chem. 2012 Mar 8;55(5):1858-67. | ||||
| REF 22 | Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit. J Med Chem. 2008 Jun 12;51(11):3065-8. | ||||
| REF 23 | Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. J Med Chem. 2008 Mar 27;51(6):1695-705. | ||||
| REF 24 | Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. J Med Chem. 2008 Mar 27;51(6):1668-80. | ||||
| REF 25 | Discovery of amido-benzisoxazoles as potent c-Kit inhibitors. Bioorg Med Chem Lett. 2008 Sep 15;18(18):5115-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.